Maravai LifeSciences Quarterly Income Statements Chart
Quarterly
|
Annual
Maravai LifeSciences Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 47,397,000 | 46,850,000 | 56,406,000 | 65,200,000 | 73,400,000 | 64,179,000 | 74,141,000 | 66,865,000 | 68,914,000 | 79,025,000 | 204,713,000 | 191,263,000 | 242,732,000 | 244,293,000 | 228,444,000 | 204,810,000 | 217,775,000 | 148,211,000 | |
| yoy | -35.43% | -27.00% | -23.92% | -2.49% | 6.51% | -18.79% | -63.78% | -65.04% | -71.61% | -67.65% | -10.39% | -6.61% | 11.46% | 64.83% | |||||
| qoq | 1.17% | -16.94% | -13.49% | -11.17% | 14.37% | -13.44% | 10.88% | -2.97% | -12.79% | -61.40% | 7.03% | -21.20% | -0.64% | 6.94% | 11.54% | -5.95% | 46.94% | ||
| operating expenses: | |||||||||||||||||||
| cost of revenue | 39,629,000 | 39,125,000 | 37,444,000 | 36,826,000 | 38,271,000 | 38,335,000 | 35,108,000 | 36,686,000 | 43,273,000 | 33,676,000 | 53,253,000 | 38,176,000 | 37,496,000 | 40,032,000 | 40,633,000 | 32,047,000 | 37,513,000 | 30,368,000 | |
| gross profit | 7,768,000 | 7,725,000 | 18,962,000 | 28,374,000 | 35,129,000 | 25,844,000 | 39,033,000 | 30,179,000 | 25,641,000 | 45,349,000 | 151,460,000 | 153,087,000 | 205,236,000 | 204,261,000 | 187,811,000 | 172,763,000 | 180,262,000 | 117,843,000 | |
| yoy | -77.89% | -70.11% | -51.42% | -5.98% | 37.00% | -43.01% | -74.23% | -80.29% | -87.51% | -77.80% | -19.36% | -11.39% | 13.85% | 73.33% | |||||
| qoq | 0.56% | -59.26% | -33.17% | -19.23% | 35.93% | -33.79% | 29.34% | 17.70% | -43.46% | -70.06% | -1.06% | -25.41% | 0.48% | 8.76% | 8.71% | -4.16% | 52.97% | ||
| gross margin % | 16.39% | 16.49% | 33.62% | 43.52% | 47.86% | 40.27% | 52.65% | 45.13% | 37.21% | 57.39% | 73.99% | 80.04% | 84.55% | 83.61% | 82.21% | 84.35% | 82.77% | 79.51% | |
| selling, general and administrative | 38,575,000 | 39,564,000 | 41,243,000 | 39,087,000 | 40,556,000 | 40,885,000 | 38,478,000 | 38,864,000 | 35,377,000 | 38,671,000 | 37,203,000 | 30,795,000 | 28,061,000 | 33,200,000 | 27,553,000 | 25,189,000 | 24,085,000 | 23,237,000 | |
| research and development | 4,882,000 | 4,888,000 | 4,561,000 | 4,344,000 | 5,284,000 | 5,032,000 | 4,594,000 | 4,347,000 | 4,194,000 | 4,145,000 | 5,011,000 | 5,389,000 | 4,274,000 | 3,695,000 | 9,173,000 | 1,950,000 | 1,932,000 | 2,164,000 | |
| change in estimated fair value of contingent consideration | 140,000 | -630,000 | -178,000 | -1,195,000 | -3,355,000 | 2,385,000 | -2,316,000 | -7,800,000 | |||||||||||
| goodwill impairment | 30,449,000 | 12,435,000 | 11,912,000 | 154,239,000 | |||||||||||||||
| restructuring | 6,000 | -4,000 | -4,000 | -1,212,000 | |||||||||||||||
| total operating expenses | 113,675,000 | 96,012,000 | 94,536,000 | 234,314,000 | 82,912,000 | 83,040,000 | 81,291,000 | 82,282,000 | 80,528,000 | 76,492,000 | 95,467,000 | 74,360,000 | 62,031,000 | 76,927,000 | 77,359,000 | 47,937,000 | 63,530,000 | 55,769,000 | |
| income from operations | -66,278,000 | -49,162,000 | -38,130,000 | -169,114,000 | -9,512,000 | -18,861,000 | -7,150,000 | -15,417,000 | -11,614,000 | 2,533,000 | 109,246,000 | 116,903,000 | 180,701,000 | 167,366,000 | 151,085,000 | 156,873,000 | 154,245,000 | 92,442,000 | |
| yoy | 596.78% | 160.65% | 433.29% | 996.93% | -18.10% | -844.61% | -106.54% | -113.19% | -106.43% | -98.49% | -27.69% | -25.48% | 17.15% | 81.05% | |||||
| qoq | 34.82% | 28.93% | -77.45% | 1677.90% | -49.57% | 163.79% | -53.62% | 32.74% | -558.51% | -97.68% | -6.55% | -35.31% | 7.97% | 10.78% | -3.69% | 1.70% | 66.86% | ||
| operating margin % | -139.84% | -104.93% | -67.60% | -259.38% | -12.96% | -29.39% | -9.64% | -23.06% | -16.85% | 3.21% | 53.37% | 61.12% | 74.44% | 68.51% | 66.14% | 76.59% | 70.83% | 62.37% | |
| other income: | |||||||||||||||||||
| interest expense | -6,815,000 | -6,778,000 | -11,263,000 | -13,634,000 | -11,939,000 | -10,864,000 | -15,400,000 | -11,637,000 | -7,022,000 | -11,833,000 | -10,180,000 | -3,136,000 | -4,434,000 | -2,664,000 | -4,433,000 | -8,545,000 | -8,512,000 | -8,770,000 | |
| interest income | 3,030,000 | 3,225,000 | 6,036,000 | 7,071,000 | 7,086,000 | 7,210,000 | 7,459,000 | 7,432,000 | 6,791,000 | 6,045,000 | |||||||||
| other income | -4,062,000 | 24,000 | 43,000 | 72,000 | -2,562,000 | 106,000 | 49,000 | 66,000 | -1,620,000 | 168,000 | 914,000 | -4,000 | -1,275,000 | 7,000 | 201,000 | 78,000 | -3,000 | 3,000 | |
| income before income taxes | -74,125,000 | -52,691,000 | -46,502,000 | -175,644,000 | -16,927,000 | -22,409,000 | 656,186,000 | -20,563,000 | -13,364,000 | -4,523,000 | 95,876,000 | 113,763,000 | 174,992,000 | 166,841,000 | 143,822,000 | 151,652,000 | 145,730,000 | 89,561,000 | |
| income tax benefit | -4,288,000 | -463,250 | 311,000 | -2,435,000 | 271,000 | 17,578,000 | 18,842,000 | 11,386,000 | |||||||||||
| net income | -69,837,000 | -52,853,000 | -46,495,000 | -175,955,000 | -14,492,000 | -22,680,000 | -109,982,000 | -15,102,000 | -11,943,000 | -1,348,000 | 87,429,000 | 99,653,000 | 156,721,000 | 146,860,000 | 126,244,000 | 132,810,000 | 134,344,000 | 75,852,000 | |
| yoy | 381.90% | 133.04% | -57.72% | 1065.11% | 21.34% | 1582.49% | -225.80% | -115.15% | -107.62% | -100.92% | -30.75% | -24.97% | 16.66% | 93.61% | |||||
| qoq | 32.13% | 13.67% | -73.58% | 1114.15% | -36.10% | -79.38% | 628.26% | 26.45% | 785.98% | -101.54% | -12.27% | -36.41% | 6.71% | 16.33% | -4.94% | -1.14% | 77.11% | ||
| net income margin % | -147.34% | -112.81% | -82.43% | -269.87% | -19.74% | -35.34% | -148.34% | -22.59% | -17.33% | -1.71% | 42.71% | 52.10% | 64.57% | 60.12% | 55.26% | 64.85% | 61.69% | 51.18% | |
| net income attributable to non-controlling interests | -30,246,000 | -22,908,000 | -20,350,000 | -76,917,000 | -6,907,000 | -10,602,000 | -4,023,000 | -8,640,000 | -5,402,000 | -1,281,000 | 49,795,000 | 55,184,000 | 85,481,000 | 79,998,000 | 70,803,000 | 78,536,000 | 85,269,000 | 52,605,000 | |
| net income attributable to maravai lifesciences holdings, inc. | -39,591,000 | -29,945,000 | -26,145,000 | -99,038,000 | -7,585,000 | -12,078,000 | -105,959,000 | -6,462,000 | -6,541,000 | -67,000 | 37,634,000 | 44,469,000 | 71,240,000 | 66,862,000 | 55,441,000 | 54,274,000 | 49,075,000 | 23,247,000 | |
| net income per class a common share attributable to maravai lifesciences holdings, inc., basic and diluted | -270 | -210 | -217.5 | -700 | -50 | -90 | |||||||||||||
| weighted-average number of class a common shares outstanding, basic and diluted | 144,236,000 | 143,425,000 | 141,555,000 | 135,842,000 | 132,333,000 | ||||||||||||||
| income tax expense | 162,000 | 8,447,000 | 14,110,000 | 18,271,000 | 19,981,000 | 13,709,000 | |||||||||||||
| change in payable to related parties pursuant to the tax receivable agreement | -1,000 | -39,000 | 671,228,000 | -1,007,000 | 101,000 | -1,436,000 | -6,442,000 | ||||||||||||
| loss on extinguishment of debt | -208,000 | ||||||||||||||||||
| income tax (benefit) expense | -2,514,250 | -5,461,000 | -1,421,000 | -3,175,000 | |||||||||||||||
| net income per class a common share attributable to maravai lifesciences holdings, inc.: | |||||||||||||||||||
| basic | -800 | -50 | -50 | 0 | 280 | 340 | 540 | 510 | 430 | 460 | 440 | 240 | |||||||
| diluted | -800 | -50 | -50 | 0 | 300 | 340 | 530 | 500 | 420 | 450 | 440 | 240 | |||||||
| weighted-average number of class a common shares outstanding: | |||||||||||||||||||
| basic | 137,906,000 | 131,919,000 | 131,930,000 | 131,864,000 | 131,739,000 | 131,545,000 | 131,540,000 | 131,524,000 | 131,489,000 | 114,791,000 | 118,433,000 | 112,203,530,000 | 96,646,515,000 | ||||||
| diluted | 137,906,000 | 131,919,000 | 131,930,000 | 131,864,000 | 131,739,000 | 255,323,000 | 131,651,000 | 255,361,000 | 255,287,000 | 257,803,000 | 258,028,000 | 112,280,375,000 | 96,672,968,000 | ||||||
| gain on sale of business | -11,249,000 | ||||||||||||||||||
| change in payable to related parties pursuant to a tax receivable agreement | 2,340,000 | -3,031,000 | 3,246,000 | 5,886,000 | |||||||||||||||
| gain on sale and leaseback transaction | |||||||||||||||||||
| net income per class a common share/unit attributable to maravai lifesciences holdings, inc.: | |||||||||||||||||||
| basic | -800 | -50 | -50 | 0 | 280 | 340 | 540 | 510 | 430 | 460 | 440 | 240 | |||||||
| diluted | -800 | -50 | -50 | 0 | 300 | 340 | 530 | 500 | 420 | 450 | 440 | 240 | |||||||
| weighted-average number of class a common shares/units outstanding: | |||||||||||||||||||
| basic | 137,906,000 | 131,919,000 | 131,930,000 | 131,864,000 | 131,739,000 | 131,545,000 | 131,540,000 | 131,524,000 | 131,489,000 | 114,791,000 | 118,433,000 | 112,203,530,000 | 96,646,515,000 | ||||||
| diluted | 137,906,000 | 131,919,000 | 131,930,000 | 131,864,000 | 131,739,000 | 255,323,000 | 131,651,000 | 255,361,000 | 255,287,000 | 257,803,000 | 258,028,000 | 112,280,375,000 | 96,672,968,000 | ||||||
We provide you with 20 years income statements for Maravai LifeSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Maravai LifeSciences stock. Explore the full financial landscape of Maravai LifeSciences stock with our expertly curated income statements.
The information provided in this report about Maravai LifeSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.